

英文影印版

Fourth Edition

药物治疗学

PHARMACOTHERAPY Volume 2

第4版 下册

JOSEPH T. DIPJRO



ROBERT L. TALBERT



GARY C. YEE



GARY R. MATZKE



BARBARA G. WELLS



L. MICHAEL POSEY



Mc
Graw
Hill

科学出版社

McGraw-Hill

英 文 影 印 版

药 物 治 疗 学

第 4 版 · 下 册

PHARMACOTHERAPY

Fourth Edition • Volume 2

Joseph T. Dipiro, PharmD, FCCP

Robert L. Talbert, PharmD, FCCP, BCPS

Gary C. Yee, PharmD, FCCP

Gary R. Matzke, PharmD, FCP, FCCP

Barbara G. Wells, PharmD, FASHP, FCCP, BCPP

L. Michael Posey, RPh

科 学 出 版 社

McGraw-Hill

2 0 0 0

Joseph T. Dipiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey: Pharmacotherapy, Fourth Edition
Copyright ©1999 by McGraw-Hill Companies, Inc.
Authorized Reprinting by Science Press, A division of *China Science Publishing Group*.
All rights reserved. For sale in the People's Republic of China only.
IE ISBN 0-07-1187707

本书英文影印版由科学出版社——中国科学出版集团核心企业和美国麦格劳-希尔国际公司合作出版。未经出版者书面许可,不得以任何方式复制或抄袭本书的任何部分。

版权所有,翻印必究。

图书在版编目(CIP)数据

药物治疗学=Pharmacotherapy:英文影印版/(美)迪彼罗(Dipiro, J. T.)主编.
-4版. -北京:科学出版社,2000.9

ISBN 7-03-008734-8

I. 药… II. 迪… III. 药物治疗法-英文 IV. R453

中国版本图书馆CIP数据核字(2000)第67541号

北京市版权局版权登记号:图字01-2000-1761

科学出版社 出版

北京东黄城根北街16号
邮政编码:100717

新蕾印刷厂印刷

科学出版社发行 各地新华书店经销

*

2000年9月第一版 开本:787×1092 1/16

2000年9月第一次印刷 印张:155 3/4

印数:1-3 000 字数:5 482 000

定价:330.00元(上、下册)

(如有印装质量问题,我社负责调换〈杨中〉)

FOREWORD

We are in the midst of rapid changes as the 20th century comes to a close. Although these rapid changes are occurring in all aspects of our lives, the dynamic changes in health care have startled all health professionals. Not too long ago we had a clear and unquestioned goal of the highest possible quality of care for our patients. But as the cost of patient care increased significantly in excess of the costs of other goods and services, the concept of managed health care was developed. Some critics state that managed health care is, in reality, managed health costs, whereas supporters state that quality care can be achieved while being cost conscious. However, both critics and supporters of managed health care agree that the practices of clinicians will continue to be influenced by increased cost consciousness in health care reimbursed through both private and public programs. This is particularly the case in the area of pharmacotherapy.

We are also in a time when great advances in biomedical research are catalyzing the development of important new drugs that, in some cases, treat diseases that previously had no treatment, and in other cases, greatly improve upon previous therapies. But in some cases new drugs may not have benefits over older therapies that justify the often higher costs of the new therapy. The challenge is to welcome new drug therapies that are necessary for quality patient care and to reject those drug therapies that merely add cost without improving quality of care. Moreover, managed health care executives must realize that drug therapy, even when appearing expensive, is almost always the least costly alternative for patient care.

Just as rapid changes are occurring in health care and in drug therapies, rapid changes are also occurring in the profession of pharmacy. One hundred years ago pharmacists were compounders of prescriptions—a role now dominated by pharmaceutical manufacturers. Forty years ago pharmacists were primarily distributors of prescription drugs—a role of limited professional responsibility today. In 1966 Dean Linwood F. Tice of the Philadelphia College of Pharmacy stated,

“I predict that the counting and pouring now often alleged to be the pharmacist’s chief occupation will in time be done by technicians and eventually by automation. The pharmacist of tomorrow will function by reason of what he knows—increasing the efficiency and safety of drug therapy and working as a drug specialist in his own right. It is in this direction that pharmaceutical education must move without delay.”

I was a faculty member at the Philadelphia College of Pharmacy in 1966 and I participated in Dean Tice’s efforts to move pharmacy in a clinical direction toward what we now call pharmaceutical care.

Later, at the University of Kentucky, and for 20 years at the University of Texas, I had the good fortune to be a colleague and friend of Charles Walton. Charlie Walton

wrote the Foreword to the first edition of this textbook. His Foreword eloquently addressed the importance of pharmacotherapy in the maturing of the profession of pharmacy. Charlie stated,

“Within this book one will find the scientific foundation for the essential knowledge required of one who may aspire to specialty practice as a pharmacotherapist.”

Note that Charlie stated, “. . . scientific foundation for the essential knowledge . . .” One thing Charlie Walton taught me was that the clinical pharmacy specialists he wanted to educate and train could not take any short cuts—the pharmacotherapist had to be a clinician who had a strong scientific foundation.

When we conceived our Texas clinical program in 1973, we committed to a three year post-baccalaureate PharmD program with an integrated residency program. These students took pathophysiology, along with medical students. No short cuts. The Texas PharmD program has evolved along with the adoption of the PharmD as the only professional degree in pharmacy. The principles that existed in the 1970s in a few schools have now generally been adopted by all colleges of pharmacy. However, specialty practice as a pharmacotherapist continues to require graduate pharmacy education beyond the PharmD, just as specialty practice in medicine requires graduate medical education beyond the MD. This text continues to be intended as “the scientific foundation for the essential knowledge required of one who may aspire to specialty practice as a pharmacotherapist.”

It is interesting that Charlie Walton often stated that he was not a clinical pharmacist. I questioned his self-assessment because, in my view, he was a uniquely talented leader and motivator for patient-oriented concepts in pharmacy education and practice. However, Charlie Walton had very high standards for a pharmacist to be termed a clinical pharmacist or a pharmacotherapist. These standards should remain high as opportunities continue to expand for pharmacotherapists to enter one-on-one, collaborative practice with physicians and other health professionals. High standards will ensure the level of clinical competence needed in the pharmacotherapist to earn the respect of patients and medical colleagues.

William Miller wrote the Foreword in the second edition of *Pharmacotherapy*. Bill is a pioneer—a first generation clinical pharmacist and pharmacotherapist. He earned his PharmD at the University of Kentucky when Charlie Walton and I were on faculty. There were no pharmacy precedents for the education and training Bill received and there was no roadmap for him to follow in his career. Therefore, it was with a teacher’s pride that I read his Foreword to the second edition. Bill’s Foreword had

the orientation of a practitioner that knew our recent successes in the evolution of pharmacotherapists are only a beginning. We have successfully demonstrated potential; the continuing challenge will be to broadly improve patient care through the specialty practice of more, and better trained, pharmacotherapists. Bill stated,

"All pharmacotherapists additionally must document the effects of their actions on patient drug therapy outcomes. The relative value of Pharmacotherapy Specialists in terms of costs and benefits must be compared with those of other professionals and technology, all these costs are driving up the price of health care. We must be avid supporters of continuous quality improvement which will encourage decisions about health care delivery systems based on fact and not simply opinion or perceptions."

In the Foreword to the third edition, Milo Gibaldi stated,

"The idea of pharmaceutical care continues to enjoy near universal support in the profession, yet we have had critical lapses in organizational and academic leadership."

Practice as a clinical pharmacy specialist is no longer an experiment or pilot project. It has become a valued practice enhancing patient care. The time has come for a full commitment of organizational and academic leadership to the advancement of high quality clinical pharmacy specialty practice as well as the advancement of general practice oriented to pharmaceutical care. Strong leadership and a care-

ful strategy will be required to advance the general and specialty practices of pharmacy in ways that do not advance one type of practice at the expense of the other.

The fourth edition of this textbook is strong evidence that the profession of pharmacy is continuing its exciting progress as a clinical profession. This text could not have been written in 1966. There were not pharmacists who could have authored the material, nor were there reasonable opportunities for pharmacists to utilize the material in practice even if, somehow, the book were authored. Today we have both the authors and the opportunity to improve patient care.

I hope that someday in the future, a leading pharmacotherapist will look back at this text and judge it to be "the text" that made the difference in pharmacists truly becoming pharmacotherapists. That is how I view the text. As dean of pharmacy at the University of Texas from 1973 to 1998, I participated, along with Charlie Walton, Bob Talbert, and others, in the development of faculty and programs that were based on pharmacy being a clinical profession. Other colleges and institutions made similar commitments. I look at this text as evidence that through these efforts the profession of pharmacy has joined medicine, nursing, and dentistry as a clinical profession.

We are in the midst of a wonderful journey.

James T. Doluisio, PhD
Hoechst Roussel Professor of Pharmacy
University of Texas
College of Pharmacy
Austin, Texas
February 1999

PREFACE

The publication of the fourth edition of *Pharmacotherapy: A Pathophysiologic Approach* continues the standards and philosophies set forth by the previous editions. *Pharmacotherapy* seeks to advance the level of pharmaceutical care through understanding of pharmacotherapeutic principles. We believe that this textbook will stimulate the pharmacy student to achieve a higher level of learning; motivate the young practitioner to perform more advanced patient care; challenge established pharmacists to learn concepts missed during years of practice; and inform the profession at large about the standards of pharmaceutical care toward which all should strive.

The authors and editors have attempted to impart a process of thinking about pharmacotherapy for the student and developing practitioner. The key to this process is the pathophysiology sections, which identify mechanisms of disease as a foundation for applying pharmacotherapeutic principles and strategies. By understanding pathophysiology and principles of therapy, the student and practitioner can assess more rigorously the place of new drugs or new therapeutic approaches.

In this edition, we have reached the limits of text that can be included in one volume and therefore made carefully considered decisions on chapters to be added and deleted. The present edition includes 132 chapters, an overall reduction of four chapters from the third edition. *New chapters* have been added on "Disorders of the Pituitary Gland" and "Substance-Related Disorders."

The *structure* of chapters and *design* of pages has continued to evolve to better meet user needs. In this edition, the following new features have been included: **more structured treatment sections**, containing a different type face which sets off the material in a visual way (**see example below**), a new section on **desired outcomes** of treatment, **redrawn flow diagrams**, disease states end-of-

chapter reminders titled **principles of pharmacotherapy** which put the major points in perspective.

The overall organization of the book is retained from previous editions. The first seven chapters again provide *primers* on important fundamental information such as: **pharmacoeconomics, pharmacoepidemiology, pharmacokinetics, drug interactions, and clinical toxicology.**

Most of the remaining chapters specifically focus on disease states and maintain a *standard format* which includes the following headings: **epidemiology, pathophysiology, clinical presentation, desired outcomes, treatment, and evaluation of therapeutic outcomes.**

The textbook together with its companion works, *Pharmacotherapy Casebook: A Patient-focused Approach*, *Pharmacotherapy Handbook*, and the *Pharmacotherapy.complete* CD-ROM provide a comprehensive package of tools useful for practice and instruction. New editions of each of the companion products should be available about the time that the fourth edition is published.

The editors recognize that many areas of this text will rapidly become outdated as our understanding of disease processes increases or as new therapies are adopted. The challenge for the student and the practitioner is to integrate information from a variety of sources, form a basis for application in pharmacotherapy, and be receptive to new information as it appears in the literature or as it is gained by personal experience.

The editors are deeply indebted to the contributors for the hours spent preparing accurate, thorough, and relevant discussions of each topic. A heartfelt thank you is well earned by the personnel at Appleton & Lange, especially Cheryl Mehalik, who provided critical support, insight, and motivation at every stage.

The Editors
April 1999

Example:

► TREATMENT: Syndrome X

Syndrome X refers to the occurrence of effort angina and exercise-induced ECG changes with a normal coronary arteriogram with no evidence of structural (stenosis) or functional (spasm) abnormalities. Although the basis for this syndrome is not yet established, it is thought that syndrome X may be a result of inducible myocardial ischemia caused by impaired functional coronary reserve at the microvascular level of intramural prearteriolar vessels. It has been proposed that this defect is caused by defective prearteriolar

regulation of blood flow into the arteriolar bed with subsequent focal, sustained, compensatory release of adenosine; excessive local concentrations of adenosine are then responsible for the pain seen in this syndrome. Prearteriolar constriction may be the result of insufficient vasodilation or inappropriate vasoconstriction, or resetting of myogenic control on a segmental or generalized distribution basis.

CONTRIBUTORS

Betty J. Abate, PharmD, BCPS

Clinical Pharmacist Specialist, Infectious Diseases and Clinical Assistant Professor of Pharmacy, Grace Hospital and Wayne State University, Detroit, MI

Paul A. Abraham, MD

Associate Professor of Medicine, University of Minnesota, School of Medicine, Chief, Division of Nephrology, Department of Medicine Regions Hospital, St. Paul, MN

Val R. Adams, PharmD

Assistant Professor, College of Pharmacy, Department of Pharmacy Practice and Science, University of Kentucky, Lexington, KY

Jeffrey R. Aeschlimann, PharmD

Assistant Professor of Pharmacy Practice, School of Pharmacy University of Connecticut, Harwinton, CT

J. V. Anandan, PharmD, BCPS

Assistant Director and Adjunct Associate Professor, Department of Pharmacy, Henry Ford Hospital/Wayne State University College of Pharmacy and Allied Health Professions, Detroit, MI

Jan Dalke Anderson, PharmD, BCNSP

Medical Affairs Manager, Searle Pharmaceuticals, Denver, CO

Edward P. Armstrong, PharmD, BCPS, FASHP

Associate Professor, College of Pharmacy, Department of Pharmacy Practice and Science, University of Arizona, Tucson, AZ

George R. Bailie, MS, PharmD, PhD, FCCP

Professor of Pharmacy Practice, Adjunct Professor of Medicine, Albany College of Pharmacy and Albany Medical College, Albany, NY

Carol McManus Balmer, PharmD

Associate Professor, School of Pharmacy, University of Colorado, Denver, CO

Steven L. Barriere, PharmD, FCCP

Director, Clinical Affairs, Gilead Sciences, Foster City, CA

Larry A. Bauer, PharmD, FCP, FCCP

Associate Professor, Pharmacy & Lab Medicine, University of Washington, Seattle, WA

Jerry L. Bauman, PharmD, BCPS, FCCP, FACC

Professor and Head, Division of Clinical Pharmaceutical Sciences, College of Pharmacy, Professor Pediatrics, University of Illinois at Chicago, Chicago, IL

Terry J. Baumann, PharmD, BCPS

Clinical Manager, Pharmacy Munson Medical Center, Traverse City, MI

Eula D. Beasley, PharmD

Clinical Coordinator, Department of Pharmacy, Washington Hospital Center, Washington, DC

Brian E. Beckett, PharmD

Associate Professor of Pharmacy Practice, Department of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, and Clinical Pharmacy Specialist, Lloyd Noland Hospital, Fairfield, AL

Susan E. Beltz, PharmD

Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Florida, and Pediatric Oncology Clinical Specialist, Department of Pharmacy Services, Shands Hospital at the University of Florida, Gainesville, FL

William H. Benefield, Jr., PharmD, FASCP, BCPP

Clinical Assistant Professor Pharmacology, Clinical Psychopharmacology Programs, The University of Texas Health Sciences Center at San Antonio, Clinical Assistant Professor of Pharmacy, College of Pharmacy, The University of Texas at Austin and Clinical Pharmacologist, San Antonio State School, San Antonio, TX

Rosemary R. Berardi, PharmD, FASHP

Professor of Pharmacy and Clinical Pharmacists in Gastroenterology, The University of Michigan, College of Pharmacy and Department of Pharmacy, University of Michigan Health System, Ann Arbor, MI

Richard C. Berchou, PharmD

Clinical Neuroscience Program, Sinai Hospital, Detroit, MI

Joseph S. Bertino, Jr., PharmD, FCCP

Co-Director, Clinical Pharmacology Research Center, Assistant Director, Clinical Pharmacy Service, and Associate Professor of Clinical Pharmacology, Bassett Healthcare/Columbia University College of Physicians and Surgeons, Cooperstown, NY

Larry E. Boh, MS

Professor and Chair, Pharmacy Practice Division, School of Pharmacy, University of Wisconsin, Madison, WI

John A. Bosso, PharmD, FCCP, BCPS

Professor and Head, Division of Clinical Pharmacy Sciences, College of Pharmacy, Professor of Pediatrics, College of Medicine, Medical University of South Carolina, Charleston, SC

Bradley A. Boucher, PharmD, BCPS, FCCP

Professor of Clinical Pharmacy and Neurosurgery, Department of Clinical Pharmacy, University of Tennessee, Memphis, TN

J. Chris Bradberry, PharmD

Department of Pharmacy Practice and Pharmacoeconomics, College of Pharmacy, The University of Tennessee-Memphis, Memphis, TN

Rex O. Brown, PharmD

Professor, Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee, and Nutrition Support Pharmacist, Department of Pharmacy, Regional Medical Center at Memphis and UT Bowld Hospital, Memphis, TN

Kathryn K. Bucci, PharmD, BCPS

Associate Professor Family Medicine, Clinical Associate Professor of Pharmacy Practice, Medical University of South Carolina, Family Practice Residency Program, Self Memorial Hospital, Charleston, SC

Gilbert J. Burckart, PharmD, FCCP

Professor of Pharmaceutical Science, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA

Mark B. Burlingame, PharmD, BCPS

Clinical Coordinator, Pharmacy Services, Department of Veterans Affairs Medical Center, and Clinical Associate Professor, Department of Pharmacy Practice, College

of Pharmacy, University of Florida, Gainesville, FL

Henry I. Bussey, PharmD

University of Texas Health Science Center-San Antonio, Clinical Pharmacy, Austin, TX

Karim A. Calis, PharmD, MPH, BCPS, BCNSP, FASHP

Clinical Specialist, Endocrinology and Women's Health, Coordinator, Drug Information Service, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, Clinical Associate Professor, University of Maryland, Baltimore, MD, Associate Clinical Professor, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA

Deborah Stier Carson, PharmD, BCPS

Associate Professor of Pharmacy Practice, Assistant Professor of Family Medicine, Medical University of South Carolina, Charleston, SC

Peggy L. Carver, PharmD

Associate Professor of Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI

Daniel T. Casto, PharmD, FCCP

Associate Professor of Pharmacy and Pediatrics, College of Pharmacy, University of Texas Health Science Center, San Antonio, TX

Katherine Hammond Chessman, PharmD, BCNSP, BCPS

Associate Professor, Department of Pharmacy Practice, Medical University of South Carolina and Clinical Pharmacy Specialist, Pediatrics/Pediatric Surgery, Medical University of South Carolina, Children's Hospital, Charleston, SC

Marie A. Chisholm, PharmD

Assistant Professor Pharmacy Practice, The University of Georgia College of Pharmacy, Assistant Clinical Professor of Medicine, Medical College of Georgia, Augusta, GA

Susan K. Chuck, PharmD

Colleges of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, IL

Peter A. Chyka, PharmD, ABAT, FAACT

Professor, Departments of Pharmacy Practice and Pharmacoeconomics and Clinical

Pharmacy, College of Pharmacy, University of Tennessee, Memphis, and Executive Director, Southern Poison Center, Memphis, TN

Ann C. Collier, MD

Professor of Medicine, School of Medicine, University of Washington Health Science Center, Seattle, WA

Thomas J. Comstock, PharmD

Associate Professor, Department of Pharmacy & Pharmaceuticals, School of Pharmacy, Medical College of Virginia, VA Commonwealth University, Richmond, VA

Stephen Joel Coons, PhD

Associate Professor, Division of Social and Administrative Sciences, College of Pharmacy, The University of Arizona, Tucson, AZ

Margaret K. Cramer, MD, FACOG

Division Chief, Obstetrics and Gynecology, Athens Regional Medical Center, Athens, GA

M. Lynn Crismon, PharmD, FCCP, BCPP

Professor and Southwestern Drug Corporation Centennial Fellow in Pharmacy, Co-Director, Texas Medication Algorithm Project, College of Pharmacy, The University of Texas at Austin, Austin, TX

Michael A. Crouch, PharmD, BCPS

Assistant Professor, School of Pharmacy, Virginia Commonwealth University, Richmond, VA

Clarence E. Curry, Jr., PharmD

Associate Professor, College of Pharmacy, Nursing and Allied Health Sciences, Howard University, Washington, DC

Christina Dalmady-Israel, PharmD, BCPS

Clinical Liaison, Medical Affairs, Roche Labs, Inc.

Larry H. Danziger, PharmD

Professor and Co-Director, Section of Infectious Diseases, College of Pharmacy, University of Illinois, Chicago, IL

Joseph F. Dasta, MS, FCCM

Professor, College of Pharmacy, Experimental and Clinical Pharmacology, The Ohio State University, Columbus, OH

Lisa E. Davis, PharmD, FCCP, BCPS

Associate Professor, Department of Phar-

macy Practice, Philadelphia College of Pharmacy, Philadelphia, PA

Renee M. DeHart, PharmD

Assistant Professor, Department of Pharmacy Practice, Samford University, McWhorter School of Pharmacy, and Clinical Pharmacy Specialist, Department of Pharmacy, Birmingham Baptist Medical Center, Princeton, Birmingham, AL

Jeffrey C. Delafuente, MS, FCCP

Professor and Director of Geriatrics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA

Michel Deschênes, MD

Chargé d'enseignement, Médecine D'Urgence, Chuq, Pavillon Chul, Quebec, Canada

Mariela Diaz-Linares, PharmD

Clinical Assistant Professor of Pharmacy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL

Joseph T. DiPiro, PharmD, FCCP

Panoz Professor, College of Pharmacy, Head, Department of Clinical and Administrative Sciences, University of Georgia College of Pharmacy; Clinical Professor of Surgery, Medical College of Georgia, Augusta, Georgia

Paul L. Doering, MS

Distinguished Service Professor of Pharmacy Practice, University of Florida, Gainesville, FL

Julie A. Dopheide, PharmD, BCPP

Assistant Professor, Clinical Pharmacy, USC School of Pharmacy, Los Angeles, CA

Peter G. Dorson, PharmD, BCPP

Director of Psychiatric Pharmacy Services, Austin State Hospital, Austin, TX

Steve C. Ebert, PharmD

Clinical Specialist, Infectious Diseases and Clinical Associate Professor, Department of Pharmacy, Meriter Hospital and School of Pharmacy, University of Wisconsin, Madison, WI

Andrea E. Eggert, PharmD, BCPP

Research Scientist and Clinical Assistant Professor, College of Pharmacy, The University of Texas at Austin, Austin, TX

Victor A. Elsberry, PharmD, BCNSP

Assistant Professor, College of Pharmacy,

Department of Pharmacy Practice and Science, University of Arizona, Tucson, AZ

Sharon M. Erdman, PharmD

Department of Pharmacy Practice and Pharmacoeconomics, College of Pharmacy, Loyola Medical Center, Maywood, IL

Brian L. Erstad, PharmD

Associate Professor, College of Pharmacy, The University of Arizona, Tucson, AZ

Susan C. Fagan, PharmD, BCPS, FCCP

Associate Professor of Pharmacy Practice, College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI

Martha P. Fankhauser, MS Pharm, FASHP

Clinical Associate Professor, Department of Pharmacy Practice and Science, College of Pharmacy, The University of Arizona, Tucson, AZ

Sally A. Felton, PharmD

Clinical Oncology Specialist, Director, Investigational Drug Section, Institute of Drug Development, San Antonio, TX

Rebecca S. Finley, PharmD, MS

Chairman, Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA

Douglas N. Fish, PharmD, BCPS

Assistant Professor of Pharmacy, Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO

John O. Fleming, MD

Professor, Neurology, University of Wisconsin, Madison, WI

Courtney V. Fletcher, PharmD

Professor, College of Pharmacy, Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN

Reginald F. Frye, PharmD, PhD

Assistant Professor, Department of Pharmaceutical Sciences, School of Pharmacy, Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, PA

Peter Gal, PharmD, BCPS, FCCP, FASHP

Director, Pharmacy Research, Pharmacotherapy and Education Greensboro Area

Health Education Center, Moses Cone Health System, Greensboro, NC; Clinical Professor, School of Pharmacy, University of North Carolina, Chapel Hill, NC

William R. Garnett, PharmD, FCCP

Professor of Pharmacy and Pharmaceutics, Professor of Neurology, Medical College of Virginia, Richmond, VA

Stephen A. Geraci, MD

Assistant Professor, Departments of Medicine, Pharmacology, and Clinical Pharmacy, Colleges of Medicine and Pharmacy, University of Tennessee at Memphis, Memphis, TN

Barry E. Gidal, PharmD

Associate Professor, School of Pharmacy, Department of Neurology, University of Wisconsin, Madison, WI

Mark A. Gill, PharmD

Professor of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, CA

Mark L. Glover, PharmD

Assistant Professor, College of Pharmacy, Department of Pharmacy Practice and Science, Nova Southeastern University, Ft. Lauderdale, FL

Barry R. Goldspiel, PharmD, BCPS, FASHP

Oncology Clinical Pharmacy Specialist, Pharmacy Department, N. I. H. Clinical Center, Bethesda, MD

Nina M. Graves, PharmD, FCCP

Senior Clinical Evaluation Manager, Medtronic Neurological, Minneapolis, MN

John G. Gums, PharmD

Professor of Pharmacy and Medicine, Departments of Pharmacy Practice and Community Health Family Medicine, University of Florida Colleges of Pharmacy and Medicine, Gainesville, FL

Philip D. Hall, PharmD, BCPS

Associate Professor, College of Pharmacy, Medical University of South Carolina, Charleston, SC

Nina H. Han, PharmD

Clinical Assistant Professor, Department of Pharmacy Practice, University of Illinois College of Pharmacy, Chicago, IL

Joseph T. Hanlon, PharmD, MS, BCPS, FASCP, FASHP

Clinical Associate Professor, School of Pharmacy, University of North Carolina, Chapel Hill, NC; Coordinator of Pharmacogeriatrics, Center for the Study of Aging and Human Development, and Associate Research Professor, Department of Medicine, Duke University Medical Center; and Clinical Pharmacist Specialist in Geriatrics at the Geriatric Research, Education and Clinical Center and Senior Research Fellow, Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, Durham, NC

J. William Harbilas, PharmD, BCPS

Clinical Specialist, Ambulatory Services, Clinical Assistant Professor, Department of Pharmacy, Shands at the University of Florida, Gainesville, FL

Thomas C. Hardin, PharmD, FCCP

Clinical Coordinator, Pharmacy Services, South Texas Veterans Health Care System, San Antonio, TX

David W. Hawkins, PharmD

Professor of Pharmacy, University of Georgia, Athens Georgia; Clinical Professor of Medicine, Medical College of Georgia, Augusta, GA

Peggy E. Hayes, PharmD

Senior Strategic Consultant, Quintiles CNS Therapeutics, San Diego, CA

Thomas K. Hazlet, PharmD, DrPH

Assistant Professor of Pharmacy, Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA

Amy M. Heck, PharmD

Specialized Resident in Drug Information Practice and Pharmacotherapy, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD

Karen L. Heim-Duthoy, PharmD, FCCP

Associate Professor, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, and Clinical Scientist, Hennepin County Medical Center, Division of Nephrology, Minneapolis, MN

Katherine C. Herndon, PharmD, BCPS

Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, McWhorter School of Pharmacy, Samford University and Clinical Pharmacy

Specialist, Department of Veterans Affairs Medical Center, Birmingham, AL

AnhThu D. Hoang, PharmD

Infectious Disease Fellow, University of Minnesota, St. Paul-Ramsey Medical Center, St. Paul, MN

Motria M. Horodysky, PharmD, BCPS

Assistant Professor of Clinical Pharmacy, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA

Mark W. Jackson, MD

Staff Physician at Baptist Hospital of East Tennessee and Fort Sanders Regional Medical Center, Knoxville, TN

Stephen W. Janning, PharmD

Clinical Coordinator, Department of Pharmacy, Duke University Medical Center, Durham, NC

Douglas D. Janson, PharmD, BCNSP

Associate Professor, Department of Pharmacy and Therapeutics, University of Pittsburgh, School of Pharmacy and Nutrition Support Specialist, University of Pittsburgh Medical Center Health System, Pittsburgh, PA

Donna M. Jermain, PharmD, BCPP

Coordinator of Pharmacy Research and Education, Scott White Memorial Hospital, Assistant Professor, Department of Medicine and Psychiatry, College of Medicine, Texas A&M Health Science Center, and Clinical Associate Professor, College of Pharmacy, University of Texas at Austin, Austin, TX

Thomas E. Johns, PharmD, BCPS

Clinical Specialist, Infectious Diseases, Department of Pharmacy, Shands at the University of Florida, Gainesville, FL

Heather J. Johnson, PharmD

Associate Professor, Department of Pharmacy and Therapeutics, University of Pittsburgh and Clinical Pharmacist, Ambulatory Care Pharmacy, University of Pittsburgh Medical Center Health System, Pittsburgh, PA

Julie A. Johnson, PharmD, BCPS, FCCP

Associate Professor, Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, FL

Lori A. Jones, PharmD

Director of Experience Programs, Clinical Assistant Professor, College of Pharmacy, University of Georgia, Augusta, GA

Thomas N. Kakuda, PharmD

Infectious Diseases Fellow, College of Pharmacy, Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN

Alan K. Kamada, PharmD

National Jewish Center of Immunology and Respiratory Disease, Department of Pediatrics, Denver, CO

Judith C. Kando, PharmD, BCPP

Executive Director, Massachusetts Project, Medical Management TM, Clinical Instructor, Harvard Medical School, Boston, MA

Janet L. Karlix, PharmD

Associate Professor, College of Pharmacy, University of Florida and Director, Transplant Clinical Pharmacology Research Center, Gainesville, FL

Peter W. Kazakoff, PharmD

Assistant Professor, School of Pharmacy, University of Colorado, Denver, CO

H. William Kelly, PharmD, FCCP, BCPS

Professor of Pharmacy and Pediatrics, College of Pharmacy, University of New Mexico Health Science, Albuquerque, MN

Mehmood A. Khan, MD, FACE

Assistant Professor, School of Medicine, University of Minnesota and Director, Division of Endocrinology, Department of Medicine, Hennepin County Medical Center, Minneapolis, MN

Robert A. Kilroy, PharmD, BCPS

Clinical Associate Professor, Department of Pharmacy Practice, University of Florida College of Pharmacy and Clinical Specialist, Department of Pharmacy Services, Shands Hospital at the University of Florida, Gainesville, FL

William R. Kirchain, PharmD, CDE

Associate Professor of Pharmacy Practice, University of the Sciences in Philadelphia, Philadelphia College of Pharmacy, Philadelphia, PA

Cynthia K. Kirkwood, PharmD

Assistant Professor, Pharmacy and Pharmaceuticals, Virginia Commonwealth University, Richmond, VA

Leroy C. Knodel, PharmD

Clinical Associate Professor, University of Texas Health Science Center at San Antonio and College of Pharmacy, Austin, TX

Jill M. Kolesar, PharmD, BCPS

Assistant Professor, School of Pharmacy, University of Wisconsin, Madison, WI

Sherri L. Konzem, PharmD

Clinical Assistant Professor, Department of Clinical Sciences and Administration, University of Houston, College of Pharmacy and Department of Family Practice, Memorial Hospital Southwest, Houston, TX

Kathleen D. Lake, PharmD, FCCP, BCPS

Director, Clinical Research and Transplant Therapeutics, Division of Nephrology and Surgery, University of Michigan Medical Center, Ann Arbor, MI

Tom A. Larson PharmD, FCCP

Associate Professor of Pharmacy Practice, Department of Pharmacy Practice, University of Minnesota, Minneapolis, MN

Alan H. Lau, PharmD, FCCP

Associate Professor, Department of Pharmacy Practice, College of Pharmacy, University of Illinois, Chicago, IL

Timothy S. Lesar, PharmD

Director of Pharmacy, Department of Pharmacy, Albany Medical Center, Albany, NY

Matthew J. Lewis, PharmD, BCPS

Clinical Assistant Professor, Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota and Clinical Scientist, Hennepin County Medical Center, Division of Nephrology, Minneapolis, MN

Peter A. LeWitt, MD

Associate Professor of Neurology, Clinical Neuroscience Program, Sinai Hospital, Wayne State University, Detroit, MI

Celeste M. Lindley, PharmD, MS, FCCP, BCPS

Associate Professor, School of Pharmacy, University of North Carolina, Chapel Hill, NC

Gwynn D. Long, MD

Associate Professor of Medicine, Bone Marrow Transplantation Program, Duke University Medical Center, Durham, NC

R. Leon Longe, PharmD

Professor, University of Georgia College of Pharmacy and Medical College of Georgia, Augusta, GA

Larry M. Lopez, PharmD, FCCP

Professor and Chairman, College of Pharmacy, University of Florida, Gainesville, FL

William L. Macias, MD, PhD

Associate Professor of Medicine, Department of Medicine, Indiana University School of Medicine, and Clinical Research Physician, Eli Lilly & Company, Indianapolis, IN

Patricia A. Marken, BS Pharm, PharmD, BCPP

University of Missouri-Kansas City, Associate Professor of Pharmacy Practice and Psychiatry and Psychopharmacy Specialist, Western Missouri Mental Health Center, Kansas City, MO

Patricia L. Marshik, PharmD

Assistant Professor of Pharmacy Practice, College of Pharmacy, Health Sciences Center, Albuquerque, NM

Todd W. Mattox, BCNSP

Nutritional Support Pharmacist, Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Gary R. Matzke, PharmD, FCP, FCCP

Professor of Pharmaceutical Sciences and Medicine, Schools of Pharmacy and Medicine, Center of Clinical Pharmacology, University of Pittsburgh, Pittsburgh, PA

William N. May, MD

Assistant Professor, Pediatrics and Neurology, University of Tennessee, Memphis, Memphis, TN

J. Russel May, PharmD

Associate Director of Pharmacy, Department of Pharmacy, Medical College of Georgia Hospital and Clinics, Augusta, Georgia; Adjunct Associate Professor, Department of Clinical and Administrative Sciences, College of Pharmacy, University of Georgia, Athens, GA

Janet McCombs, PharmD

Clinical Assistant Professor, Department of Clinical and Administrative Sciences, University of Georgia, Athens, GA

Margaret E. McGuinness, PharmD

Assistant Professor, College of Pharmacy, Oregon State University, Portland, OR

Timothy R. McGuire, PharmD

Associate Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE

Patricia A. Montgomery, PharmD

Clinical Assistant Professor of Pharmacy, College of Pharmacy and Clinical Pharmacist, Department of Pharmacy, University of Michigan Health System, The University of Michigan, Ann Arbor, MI

Ashley K. Morris, PharmD, BCPS, BCOP

Clinical Associate, Bone Marrow Transplant Program, Department of Medicine, Duke University Medical Center, Durham, NC

Bruce A. Mueller, PharmD, FCCP, BCPS

Associate Professor of Clinical Pharmacy, Department of Pharmacy Practice, School of Pharmacy and Pharmacal Science, Purdue University, Indianapolis, IN

Timothy A. Mullenix, PharmD, MS

Chairman and Associate Professor, College of Pharmacy, University of South Carolina, Columbia, SC

Patricia Moynahan Mullins, PharmD

Accountant Manager, Heritage Information Systems, Richmond, VA

Milap C. Nahata, PharmD, FCCP

Kimberly Professor of Pharmacy and Pediatrics, Colleges of Pharmacy and Medicine, Ohio State University, Columbus, OH

Jean Nappi, PharmD, FCCP, BCPS

Professor and Vice Chair, Department of Pharmacy Practice, College of Pharmacy, Medical University of South Carolina, Charleston, SC

Merlin V. Nelson, PharmD, MD

Affiliated Community Medical Center, Willmar, MN

Phillip A. Nowakowski, PharmD

Clinical Assistant Professor, Department of Pharmacy Practice, North Dakota State University, College of Pharmacy, and Di-

rector of Clinical Pharmacy Services University of Illinois College of Pharmacy, Chicago, IL

Mary Beth O'Connell, PharmD, BCPS, FASHP, FCCP

Associate Professor, Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN

Laura J. Odell, PharmD

Clinical Pharmacist, Pharmacy/Family Practice, Paynesville Area Health Care System, Minneapolis, MN

Maria-Theresa Olivari, MD, FACC

Associate Cardiologist and Director, Heart Failure/Cardiac Transplant Program, Minneapolis Heart Institute, Minneapolis, MN

Shirley M. Palmer, PharmD

Assistant Professor, School of Pharmacy, Virginia Commonwealth University, Richmond, VA

Robert B. Parker, PharmD, FCCP

Associate Professor, Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee at Memphis, Memphis, TN

Charles A. Peloquin, PharmD

Director, Infectious Disease Pharmacokinetics Laboratory, and Adjoint Associate Professor, National Jewish Medical/Research Center, Schools of Pharmacy and Medicine, University of Colorado, Denver, CO

Janelle B. Perkins, PharmD, BCPS

Manager, BMT Clinical Research, Blood and Marrow Transplant Program, H. Lee Moffitt Cancer Center, Tampa, FL

Jay I. Peters, MD

Professor, Division of Pulmonary Medicine, Department of Medicine, University of Texas Health Science Center, San Antonio, San Antonio, TX

Marnie L. Peterson, PharmD

Infectious Disease Fellow, University of Minnesota/St. Paul-Ramsey Medical Center, St. Paul, MN

William P. Petros, PharmD, FCCP

Assistant Clinical Professor, Department of Medicine, Duke University Medical Center, Durham, NC

Stephanie J. Phelps, PharmD, FCCP
Professor of Clinical Pharmacy, Associate
Professor of Pediatrics, University of Ten-
nessee, Memphis, Memphis, TN

Denise Walbrandt Pigarelli, PharmD
Clinical Professor, School of Pharmacy,
University of Wisconsin, Madison, WI

Ron E. Polk, PharmD
Professor of Pharmacy and Medicine,
School of Pharmacy, Virginia Common-
wealth University, Richmond, VA

L. Michael Posey, RPh
President, Pharmacy Editorial & News
Services, Athens, Georgia

Randall A. Prince, PharmD
Professor, College of Pharmacy, Univer-
sity of Houston, Houston, TX

L. Michael Prisant, MD
Associate Professor Medicine, Medical
College of Georgia, Augusta, GA

Richard J. Ptachcinski, PharmD, FCCP
Associate Professor, Department of Phar-
macy and Therapeutics, University of
Pittsburgh and Director, Ambulatory and
Managed Care Pharmacy, University of
Pittsburgh Medical Center Health System,
Pittsburgh, PA

Mark C. Pugh, PharmD
Pharmacists Manager, First Health Ser-
vices, Corporation

Charles C. Pulliam, MS Pharm, FASHP
Associate Professor and Director, Program
on Aging, School of Pharmacy, University
of North Carolina, Chapel Hill, NC

Marsha A. Raebel, PharmD, FCCP, BCPS
Research and Education Administrator,
Clinical Adjoint Associate Professor,
Pharmacy Specialty Services, Kaiser Per-
manente Rocky Mountain Division and
University of Colorado School of Phar-
macy, Aurora, CO

Daniel W. Rahn, MD
Professor of Medicine, Vice Dean for
Clinical Affairs, Medical College of
Georgia, Augusta, GA

Charles A. Reasner, II, MD, FACE
Associate Professor and Head, Division
of Clinical Endocrinology, Department

of Medicine, University of Texas
Health Science Center-San Antonio,
San Antonio, TX

Michael D. Reed, PharmD, FCCP, FCP
Professor of Pediatrics, RB&C Hospital,
Department of Pediatrics, Case Western
Reserve University, Cleveland, OH

Pamela D. Reiter, PharmD, BCPS
Neonatal Clinical Specialist, Pediatrics,
Department of Pharmacy, University Hos-
pital, Denver, CO

Monique Richer, PharmD, MA (ed), BCPS
Assistant Professor, Faculté De Pharma-
cie, Université Laval, Quebec, Canada

Keith A. Rodvold, PharmD, FCCP, BCPS
Professor, Department of Pharmacy Prac-
tice, University of Illinois at Chicago,
Chicago, IL

David A. Rogers, MD, FACS, FAAP
Associate Professor, Department of
Surgery, Medical College of Georgia,
Augusta, GA

Douglas F. Rose, MD
Associate Professor, Pediatrics and Neu-
rology, University of Tennessee, Mem-
phis, Memphis, TN

John C. Rotschafer, PharmD, FCCP
Professor, University of Minnesota/St.
Paul-Ramsey Medical Center, St. Paul, MN

Christine M. Ruby, PharmD, BCPS
Adjunct Assistant Professor, School of
Pharmacy, University of North Carolina,
Chapel Hill, NC; Senior Fellow, Center
for the Study of Aging and Human Devel-
opment; and Clinical Pharmacists Special-
ist in Geriatrics, Department of Pharmacy,
Durham Veterans Affairs Medical Center,
Durham, NC

Maria I. Rudis, PharmD, ABAT, BCPS
Assistant Professor, Department of Clini-
cal Pharmacy and Emergency Medicine,
USC Schools of Pharmacy and Medicine,
Los Angeles, CA

Michael J. Rybak, PharmD, FCCP, BCPS
Professor of Pharmacy and Medicine, De-
partment of Pharmacy Practice, Wayne
State University, Detroit, MI

Lisa A. Sanchez, PharmD, BCPS
President, PE Applications, Inc.,
Boston, MA

Robert R. Schade, MD
Professor and Chief, Department of Medi-
cine, Section of Gastroenterology and He-
patology, Medical College of Georgia,
Augusta, GA

Lauren S. Schlesselman, PharmD
Adult Internal Medicine Pharmacy Prac-
tice Resident, Veteran's Administration
Medical Center, Gainesville, FL

Michael J. Schmidt, PharmD
Clinical Pharmacist, Pharmacy/Family
Practice, Clement Zablocki VA Medical
Center, Milwaukee, WI

Mark E. Schneiderhan, BS Pharm, PharmD, BCPP
Clinical Assistant Professor, Pharmacy
Practice, University of Illinois, Chicago, IL

Marieke Dekker Schoen, PharmD, BCPS
Clinical Associate Professor, Department
of Pharmacy Practice and Science, Col-
lege of Pharmacy, University of Illinois at
Chicago, Chicago, IL

Nathan J. Schultz, PharmD, BCPS
Clinical Assistant Professor, University of
Minnesota, College of Pharmacy, and
Vice President, Pharmaceutical Manage-
ment Operation, Diversified Pharmaceuti-
cal Services, Inc, SmithKline Beecham,
Edina, MN

Arthur A. Schuna, MS, FASHP
Clinical Professor, Clinical Pharmacy Co-
ordinator, William S. Middleton VA Med-
ical Center, University of Wisconsin,
Madison, WI

Rowena N. Schwartz, PharmD
Associate Professor of Pharmacy and
Therapeutics, Department of Pharmacy
and Therapeutics, University of Pittsburgh,
School of Pharmacy, Pittsburgh, PA

Christopher L. Shaffer, PharmD
Clinical Specialist, Intensive Care, Depart-
ment of Pharmaceutical Services, Chil-
dren's Hospital, Adjunct Assistant Profes-
sor, Department of Pharmacy Practice,
Creighton University, Omaha, NE

David C. Shelledy, PhD
Associate Professor and Chairman,
Department of Respiratory Care, Univer-

sity of Texas Health Science Center, San Antonio, TX

Penny S. Shelton, PharmD, FASCP

Assistant Professor, School of Pharmacy, Campbell University; and Clinical Specialist in Geriatrics, Dorothea Dix Hospital, Raleigh, NC

Ralph A. Slaker, PharmD

Clinical Assistant Professor, Department of Pharmacy Practice, North Dakota State University, College of Pharmacy, and Director of Clinical Pharmacy Services, Chronimed Inc., Minnetonka, MN

Jerry D. Smith, PharmD

Clinical Fellow, Departments of Pharmacy Practice and Family Medicine, University of Florida, Gainesville, FL

Steven P. Smith, PharmD, BCPS

Adult Oncology Clinical Specialist, Department of Pharmacy, Shands at the University of Florida, Gainesville, FL

Alka Z. Somani, PharmD

Assistant Professor of Pharmacy and Therapeutics and Clinical Pharmacist, University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, PA

Roger W. Sommi, BS Pharm, PharmD, BCPP

Associate Professor of Pharmacy Practice and Psychiatry, Division of Pharmacy Practice, University of Missouri-Kansas City Schools of Pharmacy and Medicine, Kansas City, MO

Thomas T. Sproat, PharmD, BCPS, PA-C

Vice-President, Health Care Education, Cortex Communications, Inc., Tampa, FL

John V. St. Peter, PharmD, BCPS

Associate Professor, College of Pharmacy, University of Minnesota and Pharmacotherapy Specialist, Division of Endocrinology, Department of Medicine, Hennepin County Medical Center, Minneapolis, MN

Wendy L. St. Peter, PharmD, BCPS

Associate Dean for Professional Education, Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, and Clinical Scientist, Hennepin County Medical Center, Division of Nephrology, Minneapolis, MN

Chester T. Stafford, MD

Professor of Medicine and Pediatrics, Section of Allergy/Immunology, Medical College of Georgia, Augusta, GA

Condit F. Steil, PharmD, CDE

McWhorter School of Pharmacy, Samford University, Birmingham, AL

Andy Stergachis, PhD

Professor of Pharmacy and Epidemiology, Chairman, Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA

Mark A. Stratton, PharmD, BCPS, FASHP

Professor and Chair, Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Houston, TX

Kathleen A. Stringer, PharmD, FCCP

Associate Professor, School of Pharmacy, University of Colorado, Denver, CO

Robert L. Talbert, PharmD, FCCP, BCPS

Professor and Division Head, College of Pharmacy, University of Texas at Austin, Austin; Professor, Departments of Medicine and Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas

A. Thomas Tayler, PharmD

Associate Professor, University of Georgia College of Pharmacy and Clinical Professor, Medical College of Georgia, Augusta, GA

Kathleen M. Teasley-Strausburg, MS, RPh, BCNSP

Nutrition Support/Pharmacy Consultant, Lakewood, CO

Karen A. Theesen, PharmD, BCPP

Associate Professor of Pharmacy Practice and Psychiatry, Department of Pharmacy Practice, Creighton University, Omaha, NE

Philip Toltzis, MD

Assistant Professor of Pediatrics, RB&C Hospital, Department of Pediatrics, Case Western Reserve University, Cleveland, OH

Amy Wells Valley, PharmD, BCPS

Oncology Pharmacy Specialist, South Texas Veterans HealthCare System, Audie L. Murphy Division, San Antonio, TX

Bertil Wagner, PharmD, FCCM

College of Pharmacy, The State University of New Jersey, Piscataway, NJ

Sharon M. Watling, PharmD, BCPS

Clinical Specialist, Critical Care; Assistant Professor, Departments of Pharmacy and Medicine, University of Missouri, Columbia, MO

K. M. A. Welch, MD

Director, NMR and Headache Research Centers, Neurology, Henry Ford Hospital, Detroit, MI

Barbara G. Wells, PharmD, FASHP, FCCP, BCPP

Professor and Dean, Idaho State University College of Pharmacy, Pocatello, ID

Dennis P. West, PhD, FCCP

Professor of Dermatology, Northwestern University Medical School, Professor of Pharmacy Practice, University of Illinois College of Pharmacy, Chicago, IL

K. M. A. Welch, MD

Senior Associate Dean of Research and Graduate Studies, University of Kansas School of Medicine, KU Medical Center, Kansas City, KS

Dianne B. Williams, PharmD

Drug Information Specialist, Department of Pharmacy, Medical College of Georgia, Augusta, GA

David H. Wright, PharmD

Infectious Disease Resident, University of Minnesota/St. Paul-Ramsey Medical Center, St. Paul, MN

Jack A. Yanovski, MD, PhD

Chief, Unit of Growth and Obesity, Section on Women's Health, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD

Gary C. Yee, PharmD, FCCP

Professor and Chair, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE

William Zamboni, PharmD, BCPS, FASHP

Assistant Professor, Program of Molecular Therapeutics and Drug Delivery, University of Pittsburgh Cancer Institute, Pittsburgh, PA

GUIDING PRINCIPLES OF PHARMACOTHERAPY

1. There should be a justifiable indication for every medication that a patient receives.
2. A medication should be used at the lowest dosage and for the shortest duration that is likely to achieve the desired outcome.
3. Do not use more than one medication when one alone will be adequate.
4. Newly approved medications should be used only if there are clear advantages over older medications.
5. Whenever possible, the selection of a medication regimen should be based on evidence obtained from controlled clinical trials.
6. The timing of drug administration should be considered as a possible influence on drug efficacy, adverse effects, and interactions with other drugs and food.
7. A medication regimen should be simplified as much as possible to enhance patient compliance.
8. A patient's perception of illness or the risks and benefits of therapy should be recognized as possibly affecting compliance and treatment outcomes.
9. Careful observation of a patient's response to treatment is necessary to confirm efficacy, prevent, detect, or manage adverse effects, assess compliance, and determine the need for dosage adjustment or discontinuation of drug therapy.
10. To enhance compliance, choose a medication regimen that the patient can afford.
11. A medication should not be given by injection when giving it by mouth would be just as effective and safe.
12. Before medications are used, lifestyle modifications should be made, when indicated, to obviate the need for drug therapy or enhance pharmacotherapy outcomes.
13. Initiation of a drug regimen should be done with full recognition that a medication may cause a disease, sign, symptom, syndrome, or abnormal laboratory test.
14. When a variety of drugs are equally efficacious and equally safe, the drug which results in the lowest health care cost or is most convenient for the patient should be chosen.
15. When making a decision about drug therapy for individual patients, societal effects should be considered.
16. It is important to recognize the possible reasons for failure of medication regimens, which include poor compliance, improper drug dose or interval, misdiagnosis, concurrent illness, interactions with foods and drugs, environmental factors, or genetic factors.

Joseph T. DiPiro, PharmD, FCCP

Barbara G. Wells, PharmD, FASHP, FCCP, BCPP

David W. Hawkins, PharmD

August 17, 1998

CONTENTS

Foreword	xiii
Preface	xv
Contributors	xvii
Guiding Principles of Pharmacotherapy	xxv

SECTION 1: BASIC CONCEPTS 1

L. Michael Posey, RPh, Section Editor

1 Pharmacoeconomics: Principles	1
<i>Lisa A. Sanchez, PharmD, BCPS</i>	
2 Health Outcomes and Quality of Life	12
<i>Stephen Joel Coons, PhD</i>	
3 Clinical Pharmacokinetics and Pharmacodynamics	21
<i>Larry A. Bauer, PharmD, FCP, FCCP</i>	
4 Pediatrics	44
<i>Milap C. Nahata, PharmD, FCCP</i>	
5 Geriatrics	52
<i>Joseph T. Hanlon, PharmD, MS, BCPS, FASCP, FASHP</i>	
<i>Christine M. Ruby, PharmD, BCPS</i>	
<i>Penny S. Shelton, PharmD, FASCP</i>	
<i>Charles C. Pulliam, MS Pharm, FASHP</i>	
6 Pharmacoepidemiology	62
<i>Andy Stergachis, PhD</i>	
<i>Thomas K. Hazlet, PharmD, DrPH</i>	
7 Clinical Toxicology	70
<i>Peter A. Chyka, PharmD, ABAT, FAACT</i>	

SECTION 2: CARDIOVASCULAR DISORDERS 91

*Robert L. Talbert, PharmD, FCCP, BCPS
Section Editor*

8 Cardiovascular Testing	91
<i>Margaret E. McGuinness, PharmD</i>	
<i>Robert L. Talbert, PharmD, FCCP, BCPS</i>	
9 Cardiopulmonary Resuscitation	118
<i>Lori A. Jones, PharmD</i>	
10 Hypertension	131
<i>David W. Hawkins, PharmD</i>	
<i>Henry I. Bussey, PharmD</i>	
<i>L. Michael Prisant, MD</i>	
11 Heart Failure	153
<i>Julie A. Johnson, PharmD, BCPS, FCCP</i>	
<i>Robert B. Parker, PharmD, FCCP</i>	
<i>Stephen A. Geraci, MD</i>	
12 Ischemic Heart Disease	182
<i>Robert L. Talbert, PharmD, FCCP, BCPS</i>	
13 Myocardial Infarction	211
<i>Kathleen A. Stringer, PharmD, FCCP</i>	
<i>Larry M. Lopez, PharmD, FCCP</i>	
14 Arrhythmias	232
<i>Jerry L. Bauman, PharmD, BCPS, FCCP, FACC</i>	
<i>Marieke Dekker Schoen, PharmD, BCPS</i>	

15 Cardiomyopathies	265
<i>Jean Nappi, PharmD, FCCP, BCPS</i>	
16 Cardiac Transplantation	280
<i>Kathleen D. Lake, PharmD, FCCP, BCPS</i>	
<i>Maria-Teresa Olivari, MD, FACC</i>	
17 Thromboembolic Disorders	295
<i>Sharon M. Erdman, PharmD</i>	
<i>Susan K. Chuck, PharmD</i>	
<i>Keith A. Rodvold, PharmD, FCCP, BCPS</i>	
18 Stroke	327
<i>J. Chris Bradberry, PharmD</i>	
19 Hyperlipidemia	350
<i>Robert L. Talbert, PharmD, FCCP, BCPS</i>	
20 Peripheral Vascular Disease	374
<i>Robert L. Talbert, PharmD, FCCP, BCPS</i>	
21 Use of Vasopressors and Inotropes in the Pharmacotherapy of Shock	392
<i>Maria I. Rudis, PharmD, ABAT, BCPS</i>	
<i>Bertil Wagner, PharmD, FCCM</i>	
<i>Joseph F. Dasta, MS, FCCM</i>	
22 Hypovolemic Shock	408
<i>Brian L. Erstad, PharmD</i>	

SECTION 3: RESPIRATORY DISORDERS 422

*Robert L. Talbert, PharmD, FCCP, BCPS,
Section Editor*

23 Pulmonary Function Testing	422
<i>Jay I. Peters, MD</i>	
<i>David C. Shelledy, PhD</i>	
24 Asthma	430
<i>H. William Kelly, PharmD, FCCP, BCPS</i>	
<i>Alan K. Kamada, PharmD</i>	
25 Chronic Obstructive Lung Disease	460
<i>Sherri L. Konzem, PharmD</i>	
<i>Mark A. Stratton, PharmD, BCPS, FASHP</i>	
26 Respiratory Distress Syndrome	478
<i>Peter Gal, PharmD, BCPS, FCCP, FASHP</i>	
<i>Sharon M. Watling, PharmD, BCPS</i>	
<i>Christopher L. Shaffer, PharmD</i>	
27 Drug-Induced Pulmonary Diseases	495
<i>Patricia L. Marshik, PharmD</i>	
<i>H. William Kelly, PharmD, FCCP, BCPS</i>	
28 Cystic Fibrosis	508
<i>John A. Bosso, PharmD, FCCP, BCPS</i>	

SECTION 4: GASTROINTESTINAL DISORDERS 521

Joseph T. DiPiro, PharmD, FCCP, Section Editor

29 Evaluation of the Gastrointestinal Tract	521
<i>Marie A. Chisholm, PharmD</i>	
<i>Mark W. Jackson, MD</i>	

30	Gastroesophageal Reflux Disease	532
	<i>Dianne B. Williams, PharmD</i>	
31	Peptic Ulcer Disease	548
	<i>Rosemary R. Berardi, PharmD, FASHP</i>	
32	Inflammatory Bowel Disease	571
	<i>Joseph T. DiPiro, PharmD, FCCP</i>	
	<i>Robert R. Schade, MD</i>	
33	Nausea and Vomiting	586
	<i>A. Thomas Taylor, PharmD</i>	
34	Diarrhea and Constipation	599
	<i>R. Leon Longe, PharmD</i>	
	<i>Joseph T. DiPiro, PharmD, FCCP</i>	
35	Portal Hypertension and Cirrhosis	614
	<i>Mark A. Gill, PharmD</i>	
	<i>William R. Kirchain, PharmD, CDE</i>	
36	Drug-Induced Liver Disease	628
	<i>William R. Kirchain, PharmD, CDE</i>	
	<i>Mark A. Gill, PharmD</i>	
37	Pancreatitis	636
	<i>Rosemary R. Berardi, PharmD, FASHP</i>	
	<i>Patricia A. Montgomery, PharmD</i>	
38	Viral Hepatitis	649
	<i>Marsha A. Raebel, PharmD, FCCP, BCPS</i>	
	<i>Shirley M. Palmer, PharmD</i>	
39	Liver Transplantation	676
	<i>Alka Z. Somani, PharmD</i>	
	<i>Gilbert J. Burckart, PharmD, FCCP</i>	

SECTION 5: RENAL DISORDERS 686

**Gary R. Matzke, PharmD, FCP, FCCP,
Section Editor**

40	Assessment of Renal Function	686
	<i>Thomas J. Comstock, PharmD</i>	
41	Acute Renal Failure	706
	<i>Bruce A. Mueller, PharmD, FCCP, BCPS</i>	
	<i>William L. Macias, MD, PhD</i>	
42	Chronic Renal Insufficiency and End-Stage Renal Disease	732
	<i>Wendy L. St. Peter, PharmD, BCPS</i>	
	<i>Matthew J. Lewis, PharmD, BCPS</i>	
43	Renal Transplantation	771
	<i>Heather J. Johnson, PharmD</i>	
	<i>Karen L. Heim-Duthoy, PharmD, FCCP</i>	
	<i>Richard J. Ptachcinski, PharmD, FCCP</i>	
44	Hemodialysis and Peritoneal Dialysis	795
	<i>Gary R. Matzke, PharmD, FCP, FCCP</i>	
	<i>George R. Bailie, MS, PharmD, PhD, FCCP</i>	
45	Drug-Induced Renal Disease	822
	<i>Paul A. Abraham, MD</i>	
	<i>Gary R. Matzke, PharmD, FCP, FCCP</i>	
46	Glomerulonephritis	845
	<i>Alan H. Lau, PharmD, FCCP</i>	
47	Drug Therapy Individualization for Patients with Renal Insufficiency	872
	<i>Reginald F. Frye, PharmD, PhD</i>	
	<i>Gary R. Matzke, PharmD, FCP, FCCP</i>	

48	Electrolyte Homeostasis	890
	<i>Nathan J. Schultz, PharmD, BCPS</i>	
	<i>Ralph A. Slaker, PharmD</i>	
49	Acid-Base Disorders	918
	<i>Robert A. Kilroy, PharmD, BCPS</i>	
	<i>Gary R. Matzke, PharmD, FCP, FCCP</i>	

SECTION 6: NEUROLOGIC DISORDERS 938

**Barbara G. Wells, PharmD, FASHP, FCCP,
BCPP, Section Editor**

50	Evaluation of Neurologic Illness	938
	<i>Susan C. Fagan, PharmD, BCPS, FCCP</i>	
	<i>K. M. A. Welch, MD</i>	
51	Multiple Sclerosis	941
	<i>Barry E. Gidal, PharmD</i>	
	<i>John O. Fleming, MD</i>	
	<i>Christina Dalmady-Isreal, PharmD, BCPS</i>	
52	Epilepsy	952
	<i>Nina M. Graves, PharmD, FCCP</i>	
	<i>William R. Garnett, PharmD, FCCP</i>	
53	Status Epilepticus	976
	<i>Stephanie J. Phelps, PharmD, FCCP</i>	
	<i>William N. May, MD</i>	
	<i>Douglas F. Rose, MD</i>	
54	Acute Management of the Head Injury Patient	991
	<i>Bradley A. Boucher, PharmD, BCPS, FCCP</i>	
	<i>Stephanie J. Phelps, PharmD, FCCP</i>	
55	Parkinson's Disease	1001
	<i>Merlin V. Nelson, PharmD, MD</i>	
	<i>Richard C. Berchou, PharmD</i>	
	<i>Peter A. LeWitt, MD</i>	
56	Pain Management	1014
	<i>Terry J. Baumann, PharmD, BCPS</i>	
57	Headache Disorders: Migraine and Cluster	1027
	<i>Brian E. Beckett, PharmD</i>	
	<i>Katherine C. Herndon, PharmD, BCPS</i>	

SECTION 7: PSYCHIATRIC DISORDERS 1039

**Barbara G. Wells, PharmD, FASHP, FCCP,
BCPP, Section Editor**

58	Evaluation of Psychiatric Illness	1039
	<i>Patricia A. Marken, BS Pharm, PharmD, BCPP</i>	
	<i>Mark E. Schneiderhan, BS Pharm, PharmD, BCPP</i>	
59	Childhood Disorders	1046
	<i>Julie A. Dopheide, PharmD, BCPP</i>	
	<i>Karen A. Theesen, PharmD, BCPP</i>	
60	Eating Disorders	1056
	<i>Patricia A. Marken, BS Pharm, PharmD, BCPP</i>	
	<i>Roger W. Sommi, BS Pharm, PharmD, BCPP</i>	
61	Alzheimer's Disease	1065
	<i>M. Lynn Crismon, PharmD, FCCP, BCPP</i>	
	<i>Andrea E. Eggert, PharmD, BCPP</i>	

62	Substance-Related Disorders: Overview and Depressants, Stimulants, and Hallucinogens	1083	77	Menstrual-Related Disorders	1342
	<i>Paul L. Doering, MS</i>			<i>Martha P. Fankhauser, MS Pharm, FASHP</i>	
63	Substance-Related Disorders: Alcohol, Nicotine, and Caffeine	1104	78	Hormone Replacement Therapy	1355
	<i>Paul L. Doering, MS</i>			<i>Mark C. Pugh, PharmD</i>	
64	Schizophrenia	1118		<i>Patricia Moynahan Mullins, PharmD</i>	
	<i>M. Lynn Crismon, PharmD, FCCP, BCPP</i>				
	<i>Peter G. Dorson, PharmD, BCPP</i>				
65	Depressive Disorders	1141			
	<i>Judith C. Kando, PharmD, BCCP</i>				
	<i>Barbara G. Wells, PharmD, FASHP, FCCP, BCPP</i>				
	<i>Peggy E. Hayes, PharmD</i>				
66	Bipolar Disorder	1161			
	<i>Martha P. Fankhauser, MS Pharm, FASHP</i>				
	<i>William H. Benefield, Jr., PharmD, FASCP, BCPP</i>				
67	Anxiety Disorders	1182			
	<i>Cynthia K. Kirkwood, PharmD</i>				
68	Obsessive-Compulsive Disorder	1197			
	<i>Barbara G. Wells, PharmD, FASHP, FCCP, BCPP</i>				
	<i>Peggy E. Hayes, PharmD</i>				
69	Sleep Disorders	1208			
	<i>Donna M. Jermain, PharmD, BCPP</i>				
SECTION 8: ENDOCRINOLOGIC DISORDERS 1219			SECTION 10: IMMUNOLOGIC DISORDERS 1366		
	<i>Robert L. Talbert, PharmD, FCCP, BCPS, Section Editor</i>			<i>Gary C. Yee, PharmD, FCCP, Section Editor</i>	
70	Diabetes Mellitus	1219	79	Function and Evaluation of the Immune System	1366
	<i>Condit F. Steil, PharmD, CDE</i>			<i>Philip D. Hall, PharmD, BCPS</i>	
71	Thyroid Disorders	1244		<i>Janet L. Karlix, PharmD</i>	
	<i>Charles A. Reasner, II, MD, FACE</i>		80	Systemic Lupus Erythematosus and Other Collagen Vascular Diseases	1378
	<i>Robert L. Talbert, PharmD, FCCP, BCPS</i>			<i>Mark B. Burlingame, PharmD, BCPS</i>	
72	Adrenal Gland Disorders	1265		<i>Jeffrey C. Delafuente, MS, FCCP</i>	
	<i>John G. Gums, PharmD</i>		81	Allergic and Pseudoallergic Drug Reactions	1393
	<i>Jerry D. Smith, PharmD</i>			<i>Joseph T. DiPiro, PharmD, FCCP</i>	
73	Pituitary Gland Disorders	1281		<i>Chester T. Stafford, MD</i>	
	<i>Amy M. Heck, PharmD</i>			<i>Lauren S. Schlesselman, PharmD</i>	
	<i>Karim A. Calis, PharmD, MPH, BCPS, BCNSP, FASHP</i>				
	<i>Jack A. Yanovski, MD, PhD</i>				
SECTION 9: GYNECOLOGIC AND OBSTETRIC DISORDERS 1298			SECTION 11: BONE AND JOINT DISORDERS 1406		
	<i>Barbara G. Wells, PharmD, FASHP, FCCP, BCPP, Section Editor</i>			<i>L. Michael Posey, RPh, Section Editor</i>	
74	Pregnancy and Lactation: Therapeutic Considerations	1298	82	Osteoporosis and Osteomalacia	1406
	<i>Janet McCombs, PharmD</i>			<i>Mary Beth O'Connell, PharmD, BCPS, FASHP, FCCP</i>	
	<i>Margaret K. Cramer, MD, FACOG</i>		83	Rheumatoid Arthritis	1427
75	Infertility	1313		<i>Arthur A. Schuna, MS, FASHP</i>	
	<i>Deborah Stier Carson, PharmD, BCPS</i>			<i>Michael J. Schmidt, PharmD</i>	
	<i>Kathryn K. Bucci, PharmD, BCPS</i>			<i>Denise Walbrandt Pigarelli, PharmD</i>	
76	Contraception	1327	84	Osteoarthritis	1441
	<i>Kathryn K. Bucci, PharmD, BCPS</i>			<i>Larry E. Boh, MS</i>	
	<i>Deborah Stier Carson, PharmD, BCPS</i>		85	Gout and Hyperuricemia	1460
				<i>David W. Hawkins, PharmD</i>	
				<i>Daniel W. Rahn, MD</i>	
			SECTION 12: DISORDERS OF THE EYES, EARS, NOSE AND THROAT 1466		
				<i>L. Michael Posey, RPh, Section Editor</i>	
			86	Glaucoma	1466
				<i>Timothy S. Lesar, PharmD</i>	
			87	Allergic Rhinitis	1479
				<i>J. Russell May, PharmD</i>	
			SECTION 13: DERMATOLOGIC DISORDERS 1489		
				<i>L. Michael Posey, RPh, Section Editor</i>	
			88	Acne and Psoriasis	1489
				<i>Nina H. Han, PharmD</i>	
				<i>Phillip A. Nowakowski, PharmD</i>	
				<i>Dennis P. West, PhD, FCCP</i>	